Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“upstream regulators of RB have been involved in cancer initiation in patients, both in familial and sporadic cases, and in several organs and tissues25–27.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [26]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Self-citationAnalysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 714
Research works printed but not linked: 1
- Walker, G.J. et al. .Mutations of the CDKN2/ p16INK4 gene in Australian melanoma kindreds. Hum. Molec. Genet. 4, 1845–1852 (1995).
Cited by
Items 301–400 of 817
Recent advances in melanoma research
Saida, T. (2001) · Journal of Dermatological Science · doi:10.1016/s0923-1811(01)00085-8 · Cited by 46
Genetic predisposition to skin cancer
Halpern, A. C., & Altman, J. F. (1999) · Current Opinion in Oncology · doi:10.1097/00001622-199903000-00010 · Cited by 46
Significance of chromosome arm 14q loss in nonpapillary renal cell carcinomas
Herbers, J., Schullerus, D., Müller, H., Kenck, C., Chudek, J. T., Weimer, J. P., Bugert, P., & Kovács, G. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199705)19:1<29::aid-gcc5>3.0.co;2-2 · Cited by 69
Self-citationRanderson‐Moor, J. A., Gaut, R. M., Turner, F., Whitaker, L. M., Barrett, J. H., dos‐Santos‐Silva, I., Swerdlow, A. J., Bishop, D. T., & Newton‐Bishop, J. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23304.x · Cited by 44
Hille, E. T. M., van Duijn, E., Gruis, N. A., Rosendaal, F. R., Bergman, W., & Vandenbroucke, J. P. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00185.x · Cited by 45
“The three known melanoma susceptibility loci are located on 1p36 (Bale et al, 1989), 12q13 (Zuo et al, 1996), and 9p21 (Kamb et al, 1994).”
BackgroundA new POT1 germline mutation—expanding the spectrum of POT1-associated cancers
Wilson, T. L. S., Hattangady, N. G., Lerário, A. M., Williams, C., Koeppe, E. S., Quinonez, S. C., Osborne, J., Cha, K. B., & Else, T. (2017) · Familial Cancer · doi:10.1007/s10689-017-9984-y · Cited by 46
“CDK4 is another less commonly observed high penetrance gene conferring a life-time melanoma risk of ~70% [8].”
BackgroundWindpassinger, C., Piard, J., Bonnard, C., Alfadhel, M., Lim, S., Bisteau, X., Blouin, S., Ali, N. A., Ng, A. Y. J., Lu, H. K., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.08.003 · Cited by 44
Dantonio, P. M., Klein, M., Freire, M. R. V. B., Araujo, C. D. N., Chiacetti, A. C., & Correa, R. G. (2018) · Bioscience Reports · doi:10.1042/bsr20180511 · Cited by 52
Post-translational Modifications (PTMs), from a Cancer Perspective: An Overview
Sharma, B. S., Prabhakaran, V., Desai, A. P., Bajpai, J., Verma, R. J., & Swain, P. K. (2019) · Oncogen · doi:10.35702/onc.10012 · Cited by 49
“This signaling is altered in many human cancers [61], in some of which impassiveness of cyclinCDK4 complex to the inhibitory signals of p15INK4B leads to inactivation of pRb by hyperphosphorylation [62].”
BackgroundGenetic susceptibility in familial melanoma from northeastern Italy
Landi, M. T., Goldstein, A. M., Tsang, S., Munroe, D. J., Modi, W., Ter‐Minassian, M., Steighner, R., Dean, M. C., Metheny, N., Staats, B. J., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.016907 · Cited by 44
“Primers for CDKN2B were as described in Liu et al 27 ; primers for the b transcript were as described in Mao et al, 28 and primers for CDK4 were described in Zuo et al 29 and Shennan et al. 30 Genome wide scan of chromosomes 1 and 9 The marker set genotyped in this study was the Applied Biosystems Inc. (ABI) linkage m…”
MethodInfluentialSelf-citationRetzer‐Lidl, M., Schmid, R. M., & Schneider, G. (2007) · International Journal of Cancer · doi:10.1002/ijc.22619 · Cited by 51
“The importance of CDK4 in tumorigenesis is seen in sporadic and familiar melanoma, where miscoding mutations in the CDK4 locus, rendering CDK4 insensitive towards INK4A inhibition, were observed.(38,39) Further experimental evidence for the fundamental role of CDK4 in tumor-formation is provided by CDK4 knock-in mice,…”
BackgroundBenefits of oral Polypodium Leucotomos extract in MM high‐risk patients
Aguilera, P., Carrera, C., Puig‐Butillé, J. A., Bádenas, C., Lecha, M., González, S., Malvehy, J., & Puig, S. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04659.x · Cited by 50
JAK/STAT signaling regulates tissue outgrowth and male germline stem cell fate in Drosophila
Singh, S. R., Chen, X., & Hou, X. S. (2005) · Cell Research · doi:10.1038/sj.cr.7290255 · Cited by 42
MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2
Gillam, M. P., Nimbalkar, D., Sun, L., Christov, K. T., Ray, D., Kaldis, P., Liu, X., & Kiyokawa, H. (2014) · Oncogene · doi:10.1038/onc.2014.3 · Cited by 45
Monnerat, C., Chompret, A., Kannengiesser, C., Avril, M., Janin, N., Spatz, A., Guinebretière, J., Marian, C., Barrois, M., Boitier, F., et al. (2007) · Familial Cancer · doi:10.1007/s10689-007-9143-y · Cited by 43
“We chose to study CDKN2A and CDK4, two melanoma susceptibility genes [17, 18]; BRCA1 and BRCA2, two BC and ovarian cancer (OC) susceptibility genes [19, 20]; and the Li-Fraumeni syndrome gene TP53 [21].”
MethodMelanoma Cell Autonomous Growth: The Rb/E2F Pathway
Halaban, R. (1999) · Cancer and Metastasis Reviews · doi:10.1023/a:1006396104073 · Cited by 46
Genetics of Cutaneous Melanoma and Nevi
Greene, M. H. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.5.467 · Cited by 42
Aune, D., Sen, A., Norat, T., Riboli, E., & Folseraas, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-90175-w · Cited by 40
Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis
Ferguson, B., Konrad Muller, H., Handoko, H. Y., Khosrotehrani, K., Beermann, F., Hacker, E., Peter Soyer, H., Bosenberg, M., & Walker, G. J. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00752.x · Cited by 41
“23; 771–780 ORIGINAL ARTICLE carrying germline mutations such as R24C and R24H (e.g. Zuo et al., 1996).”
BackgroundSelf-citationPrevalence of 9p21 deletions in UK melanoma families
Mistry, S. H., Taylor, C., Randerson‐Moor, J. A., Harland, M., Turner, F., Barrett, J. H., Whitaker, L. M., Jenkins, R. B., Knowles, M. A., Newton‐Bishop, J., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20238 · Cited by 41
“All 132 families with two or more cases of melanoma recruited to the program up to December 2003 had been studied blind with regard to the presence of coding mutations of CDKN2A and CDK4.”
BackgroundInfluentialUpdate on genetic events in the pathogenesis of melanoma
Halachmi, S., & Gilchrest, B. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200103000-00008 · Cited by 44
Systems Biology and the Molecular Circuits of Cancer
Alberghina, L., Chiaradonna, F., & Vanoni, M. (2004) · ChemBioChem · doi:10.1002/cbic.200400170 · Cited by 43
Molecular landscape of Hereditary Melanoma
Arnaut, J. R. M. B., Guimarães, I. D. S., dos Santos, A. C. E., da Silva, F. D. M. L., Machado, J. R. D. S., & de Melo, A. C. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103425 · Cited by 43
p16INK4A and p14ARF tumour suppressors in melanoma: lessons from the mouse
Walker, G. J., & Hayward, N. K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07271-9 · Cited by 41
Self-citationGoldstein, A. M., Martinez, M. M., Tucker, M. A., & Démenais, F. (2000) · PubMed · Cited by 40
Self-citationThe Complex Interplay between Nevi and Melanoma: Risk Factors and Precursors
Shreberk‐Hassidim, R., Ostrowski, S. M., & Fisher, D. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043541 · Cited by 59
“This locus encodes two tumor suppressor gene products, including the cell-cycle inhibitor p16 (INK4A) and p14 (ARF), which prevents the degradation of p53 [54,55].”
BackgroundPathways from senescence to melanoma: focus on MITF sumoylation
Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Oncogene · doi:10.1038/onc.2017.292 · Cited by 46
MYG1, novel melanocyte related gene, has elevated expression in vitiligo
Kingo, K., Philips, M., Aunin, E., Luuk, H., Karelson, M., Rätsep, R., Silm, H., Vasar, E., & Kõks, S. (2006) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2006.08.001 · Cited by 39
Retraction Note to: Identification and role of adenylyl cyclase in auxin signalling in higher plants
Ichikawa, T., Suzuki, Y., Czaja, I., Schommer, C., Leßnick, A., Schell, J., & Walden, R. M. (1998) · Nature · doi:10.1038/24659 · Cited by 39
Hino, K., Nagane, M., Fujioka, Y., & Shiokawa, Y. (2005) · Neurosurgery · doi:10.1227/01.neu.0000159716.45457.bc · Cited by 38
Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma
Nikolaou, V. A., Kang, X., Stratigos, A., Gogas, H. J., Latorre, M. C., Gabree, M., Plaka, M., Njauw, C.-N. J., Kypreou, K. P., Mirmigi, I., et al. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10551.x · Cited by 37
Melanoma Genetics: An Update on Risk-Associated Genes
Udayakumar, D., & Tsao, H. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.011 · Cited by 44
Ghiorzo, P., Bonelli, L. A., Pastorino, L., Bruno, W., Barile, M., Andreotti, V., Nasti, S., Battistuzzi, L., Grosso, M., Bianchi‐Scarrà, G., et al. (2012) · Experimental Dermatology · doi:10.1111/j.1600-0625.2012.01549.x · Cited by 38
Helgadóttir, H., Tuominen, R., Olsson, H. L., Hansson, J., & Höiom, V. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.05.050 · Cited by 42
Landsberg, J., Gaffal, E., Cron, M., Sirokay, J. D., Renn, M., & Tüting, T. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00744.x · Cited by 40
“The oncogenic germline mutation in the cyclin-dependent kinase 4 (Cdk4) contributes to melanoma development in mice and man because it functionally inactivates the tumor suppressor p16 ⁄ INK4a, which is of critical importance for oncogene-induced senescence (Michaloglou et al., 2005; Sotillo et al., 2001; Wolfel et al…”
BackgroundMolecular Markers of Tumor Progression in Melanoma
Rother, J., & Jones, D. (2009) · Current Genomics · doi:10.2174/138920209788488526 · Cited by 43
“Approximately 5-10% of melanomas have a strong familial link, and the molecular defects in most of these cases involve cell cycle regulators, particularly cyclin-dependent kinases (CDKs) and the CDK inhibitor p16 (CDKN2A) in their molecular pathogenesis [1-5].”
BackgroundTripathi�, A., Banerjee, S., Chunder, N., Roy, A. K., Sengupta, A., Roy, B., Roychowdhury, S., & Panda, C. K. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0485-z · Cited by 37
“The dominant CDK4 Arg24Cys mutation seen in melanoma, which specifically inhibits the interaction between p16 and cdk4 (Zuo et al. 1996), has not yet been studied in HNSCC samples; thus, the alterations in any one of these genes, i.e. CCND1, CDK4 and RB1, might have the same effect as that of the…”
BackgroundMethodInfluentialSoufir, N., Lacapère, J.-J., Bertrand, G., Matichard, E., Meziani, R., Mirebeau‐Prunier, D., Descamps, V., Gérard, B., Archimbaud, A., Ollivaud, L., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601503 · Cited by 41
“Two highly penetrant melanoma-predisposing genes have been identified to date, INK4aARF and Cdk4 (Hussussian et al, 1994; Kamb et al, 1994; Zuo et al, 1996).”
BackgroundMethodInfluentialCo-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
Yadav, V., Chen, S.-H., Yue, Y. G., Buchanan, S. G., Beckmann, R. P., & Peng, S.-B. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.003 · Cited by 39
Rutter, J. L., Bromley, C. M., Goldstein, A. M., Elder, D. E., Holly, E. A., Guerry, D., Hartge, P. A., Struewing, J. P., Hogg, D., Halpern, A. C., et al. (2004) · Cancer · doi:10.1002/cncr.20669 · Cited by 36
“Germline CDKN2A mutations that cosegregated with disease have been found in 20% of all melanoma-prone families evaluated,(7) and 3 families worldwide have been reported to have cosegregating CDK4 mutations.(8,9) The likelihood of finding a CDKN2A mutation in the family increases as the number of family members with me…”
BackgroundSelf-citationCDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population
Pjanova, D., Eņģele, L., Randerson‐Moor, J. A., Harland, M., Bishop, D. T., Newton‐Bishop, J., Taylor, C., Dębniak, T., Lubiński, J., Kleina, R., et al. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e328014a2cd · Cited by 36
Genetics of familial and sporadic melanoma: Clinical dermatology • Review article
Bataille, V. A. (2000) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2000.00689.x · Cited by 36
Driving the Cell Cycle to Cancer
Malumbres, M., Hunt, S. L., Sotillo, R., Martín‐Broto, J., Odajima, J., Martín, A., Dubus, P. R., Ortega, S., & Barbacid, M. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0081-0_1 · Cited by 37
Todd, M. C., Sclafani, R. A., & Langan, T. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203289 · Cited by 35
“A mutation that results in an arg to cys transition in CDK4 and renders it unable to be bound and inhibited by p16 has been reported in familial melanomas (Wolfel et al., 1995; Zuo et al., 1996).”
BackgroundThe genetics of malignant melanoma
Lomas, J., Martín‐Duque, P., Pons, M., & Quintanilla, M. (2008) · Frontiers in bioscience · doi:10.2741/3065 · Cited by 42
“A second melanoma susceptibility gene, CDK4, was found at chromosome 12q14 (34-36).”
BackgroundApplications of Genomics in Melanoma Oncogene Discovery
Berger, M. F., & Garraway, L. A. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.005 · Cited by 37
Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study
Helgadóttir, H., Isaksson, K., Fritz, I., Ingvar, C., Lapins, J., Höiom, V., Newton‐Bishop, J., & Olsson, H. L. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa088 · Cited by 35
de Snoo, F. A., Kroon, M. W., Bergman, W., ter Huurne, J., Houwing‐Duistermaat, J. J., van Mourik, L., Snels, D. G. C. T. M., Breuning, M. H., Willemze, R., Frants, R. R., et al. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.01.010 · Cited by 34
Gaffal, E., Landsberg, J., Bald, T., Sporleder, A., Sirokay, J. D., & Tüting, T. (2011) · International Journal of Cancer · doi:10.1002/ijc.25913 · Cited by 37
“This mutation has been identified in sporadic as well as hereditary cases of melanoma.(12,13) It supports melanoma growth because it prevents binding of the tumor”
BackgroundAdvances in melanoma senescence and potential clinical application
Giuliano, S., Ohanna, M., Ballotti, R., & Bertolotto, C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00820.x · Cited by 47
“In addition to p16 loss, some melanomas express p16-resistant CDKs (Zuo et al., 1996) or overexpress cyclin D1 (Sauter et al.”
BackgroundInfluentialMaestro, R., Gloghini, A., Doglioni, C., Piccinin, S., Vukosavljevic, T., Gasparotto, D., Carbone, A., & Boiocchi, M. (1997) · Blood · doi:10.1182/blood.v89.7.2523 · Cited by 34
Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis
Rodríguez, E., Quereda, V., Bellutti, F., Prchal‐Murphy, M., Partida, D., Eguren, M., Kollmann, K., de Cedrón, M. G., Dubus, P. R., Cañamero, M., et al. (2014) · Blood · doi:10.1182/blood-2014-02-555292 · Cited by 38
“Cdk4 is mostly amplified in sarcomas,(42-44) whereas the Cdk4 R24C mutation is specifically found in melanoma.(14,15) Cdk6, on the other hand, is translocated and amplified in multiple hematopoietic neoplasms such as T- and B-cell lymphomas and leukemias(45-50) and acute myeloid leukemias.”
BackgroundGenetic Determinants of Cutaneous Melanoma Predisposition
Udayakumar, D., Mahato, B., Gabree, M., & Tsao, H. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.06.002 · Cited by 45
A germline oncogenic MITF mutation and tumor susceptibility
Paillerets, B. B., Lesueur, F., & Bertolotto, C. (2013) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.10.002 · Cited by 35
Liu, J.-Y., Qian, D., He, L.-R., Li, Y.-H., Liao, Y.-J., Mai, S., Tian, X.-P., Liu, Y.-H., Zhang, J., Kung, H., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-148 · Cited by 33
“Dysfunction of the proteins involved in the p16 pathway such as deletion of the p16 gene and overexpression of CDKs of cyclin D1 will lead to Rb phosphorylation, subsequent progression of G1/S phase transition and promotion of uncontrolled cell growth/proliferation [29-34].”
Zhou, L., Wang, Y., Ou, C., Lin, Z., Wang, J., Liu, H., Zhou, M., & Ding, Z. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.06.009 · Cited by 33
Zhao, Y., Zhang, Y., Yang, Z., Li, A., & Dong, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.148 · Cited by 33
“Consistent with a tumor suppressor role of INK4A in melanomas, a germ line Arg24Cys (R24C) mutation in CDK4 has been identified in familial melanoma patients (Wolfel et al., 1995; Zuo et al., 1996).”
BackgroundGeffrotin, C., Créchet, F., Roy, P. L., Chalony, C. L., Leplat, J. J. J. J., Iannuccelli, N., Barbosa, A. S., Renard, C., Gruand, J., Milan, D., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20053 · Cited by 33
Feng, X., Hao, J., Liu, Q., Yang, L., Lv, X., Zhang, Y., Xing, L., Xu, N., & Liu, S. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24071 · Cited by 32
“…of the pathway, such as deletion or mutation of the p16 gene, amplification or the overexpression of CDKs of cyclin D, and mutations to CDKs that affect p16 binding, will lead to Rb phosphorylation and subsequent progression of G1 into S phase transition [Paggi et al., 1996; Zuo et al., 1996].”
BackgroundPopulation-Based Assessment of Non-Melanoma Cancer Risk in Relatives of Cutaneous Melanoma Probands
Larson, A. A., Leachman, S. A., Eliason, M. J., & Cannon‐Albright, L. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700507 · Cited by 36
“, 1994), CDK4 (MIM 123829) (Zuo et al., 1996; Soufir et al., 1998; Hayward, 2003), and p14/ ARF (MIM 600160) (Randerson-Moor et al.”
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma
French Familial Melanoma Study Group, Lesueur, F., de Lichy, M., Barrois, M., Durand, G., Bombled, J., Avril, M., Chompret, A., Boitier, F., Lenoir, G., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604470 · Cited by 42
“Two high-risk genes have been identified: the cell cycle regulator CDKN2A on chromosomal band 9p21 (Hussussian et al, 1994) and the cyclin-dependent kinase-4 (CDK4) on chromosomal band 12p14 (Zuo et al, 1996), the products of which are known to be components of potent tumour-suppression pathway.”
BackgroundCharacterization of melanoma susceptibility genes in high-risk patients from Central Italy
Pellegrini, C., Maturo, M. G., Martorelli, C., Suppa, M., Antonini, A., Kostaki, D., Verna, L., Landi, M. T., Peris, K., & Fargnoli, M. C. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000323 · Cited by 35
Genetic Mutations Involved in Melanoma: A Summary of Our Current Understanding
High, W. A., & Robinson, W. A. (2007) · Advances in Dermatology · doi:10.1016/j.yadr.2007.07.009 · Cited by 39
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL)
Harland, M., Goldstein, A. M., Kukalizch, K., Taylor, C., Hogg, D., Puig, S., Bádenas, C., Gruis, N. A., ter Huurne, J., Bergman, W., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.005 · Cited by 37
Self-citationTranscript Mapping in a 46-kb Sequenced Region at the Core of 12q13.3 Amplification in Human Cancers
ELKAHLOUN, A. G., Krizman, D. B., Wang, Z., Hofmann, T., Roe, B. A., & Meltzer, P. S. (1997) · Genomics · doi:10.1006/geno.1997.4727 · Cited by 32
Arrayed identification of DNA signatures
Käller, M., Lundeberg, J., & Ahmadian, A. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.1.65 · Cited by 32
“, 1994; Hayward, 2000) and CDK4, encoding cyclin dependent kinase 4 (Zuo et al., 1996; Soufir et al., 1998).”
BackgroundResponses to ultraviolet-B in cell lines from hereditary melanoma kindreds
Shannon, J., Kefford, R. F., & Mann, G. J. (2001) · Melanoma Research · doi:10.1097/00008390-200102000-00001 · Cited by 32
CDK6 and p16INK4A in lymphoid malignancies
Kollmann, K., & Sexl, V. (2013) · Oncotarget · doi:10.18632/oncotarget.1541 · Cited by 30
Genetic counseling in melanoma
Bádenas, C., Aguilera, P., Puig‐Butillé, J. A., Carrera, C., Malvehy, J., & Puig, S. (2012) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2012.01499.x · Cited by 38
“CDK4, which is an oncogene, encodes one of the binding partners of p16 (13).”
Hamilton, M., & Suri, M. (2018) · Advances in genetics · doi:10.1016/bs.adgen.2018.11.001 · Cited by 34
Aoude, L. G., Gartside, M. G., Johansson, P. A., Palmer, J. M., Symmons, J., Martin, N. G., Montgomery, G. W., & Hayward, N. K. (2015) · Twin Research and Human Genetics · doi:10.1017/thg.2015.12 · Cited by 35
“Studies have shown that 10% of cutaneous malignant melanoma (CMM) cases occur in people that have a family history of melanoma (Gruis et al., 1995; Hussussian et al., 1994; MacGeoch et al., 1994; Soufir et al., 1998; Walker et al., 1995; Zuo et al., 1996).”
BackgroundSelf-citationThe Hallmarks of Cancer Review
Hanahan, D., & Weinberg, R. A. (2000) · Cited by 34
Gjertsen, M. K., Bjørheim, J., Saeterdal, I., Myklebust, J., & Gaudernack, G. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970904)72:5<784::aid-ijc14>3.0.co;2-9 · Cited by 161
Herr, M. M., Schonfeld, S. J., Dores, G. M., Withrow, D. R., Tucker, M. A., Curtis, R. E., & Morton, L. M. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy052 · Cited by 32
Self-citationCutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
Ishitsuka, Y., Hanaoka, Y., Tanemura, A., & Fujimoto, M. (2021) · Cancers · doi:10.3390/cancers13051148 · Cited by 29
“It is noteworthy that compared with cancer-prone LOF G1 checkpoint mutations [123,125,130,131], the MAPK signaling cascade is indispensable for normal embryonic development in mice [132,133].”
BackgroundBourneuf, E., Du, Z., Estellé, J., Gilbert, H., Créchet, F., Piton, G., Milan, D., Geffrotin, C., Lathrop, M. G., Démenais, F., et al. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9334-6 · Cited by 31
“Two high-risk genes have been discovered in melanomaprone kindred, namely, CDKN2A and CDK4, both involved in cell cycle regulation through the p53/Rb pathway (Hussussian et al. 1994; Kamb et al. 1994; Soufir et al. 1998; Zuo et al. 1996 ).”
BackgroundLoss of p16INK4A stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway
Tyagi, E., Liu, B., Li, C., Liu, T., Rutter, J. P., & Grossman, D. (2017) · Oncotarget · doi:10.18632/oncotarget.19862 · Cited by 33
“Individuals with germline mutations in p16 are predisposed to melanoma [4, 5].”
Diverse roles for CDK‐associated activity during spermatogenesis
Palmer, N., Talib, S. Z. A., & Kaldis, P. (2019) · FEBS Letters · doi:10.1002/1873-3468.13627 · Cited by 31
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma
Sager, R., Backe, S. J., Ahanin, E. F., Smith, G., Nsouli, I. S., Woodford, M. R., Bratslavsky, G., Bourboulia, D., & Mollapour, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00571-8 · Cited by 29
MC1R, ASIP, TYR, and TYRP1 gene variants in a population‐based series of multiple primary melanomas
Helsing, P., Nymoen, D. A., Rootwelt, H., Vårdal, M., Akslen, L. A., Molven, A., & Andresen, P. A. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21952 · Cited by 32
“, 1994) and CDK4 (Zuo et al., 1996; Molven et al., 2005), and common, low-penetrant alleles of the pigmentation gene MC1R (Palmer et al.”
BackgroundBuecher, B., Gauthier‐Villars, M., Desjardins, L., Rouïc, L. L.-L., Lévy, C., Pauw, A. D., Bombled, J., Tirapo, C., Houdayer, C., Paillerets, B. B., et al. (2010) · Familial Cancer · doi:10.1007/s10689-010-9379-9 · Cited by 34
“CDK4 analysis has been restricted to exon 2 as no germline mutations were detected outside this exon, which contains two important P16 binding residues (Lys 22 and Arg 24) in full gene scanning [21, 22].”
BackgroundIncreased expression of the INK4a/ARF locus in polycythemia vera
Dai, C., & Krantz, S. B. (2001) · Blood · doi:10.1182/blood.v97.11.3424 · Cited by 35
Molecular pathology of melanoma
Newton‐Bishop, J. (1997) · Cancer and Metastasis Reviews · doi:10.1023/a:1005752510012 · Cited by 30
Rotolo, S., Diotti, R., Gordon, R. E., Qiao, R., Yao, Z., Phelps, R. G., & Dong, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.20865 · Cited by 35
“germline R24C mutation in CDK4 has been identified in familial melanoma patients.(15,16) This mutation abolishes CDK4 inhibition by p16 and, thus, is believed to be functionally equivalent to p16 loss.”
BackgroundHypoxia in Skin Cancer: Molecular Basis and Clinical Implications
Jeon, S., Jeon, M., Choi, S., Yoo, S., Park, S.-H., Lee, M., & Kim, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054430 · Cited by 28
Nanomedicine: A pragmatic approach for tackling melanoma skin cancer
Prajapat, V. M., Mahajan, S., Paul, P., Aalhate, M., Mehandole, A., Madan, J., Dua, K., Chellappan, D. K., Singh, S. K., & Singh, P. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104394 · Cited by 31
Cyclin‐dependent kinases as therapeutic targets in melanoma
Miller, D. M., & Flaherty, K. T. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12211 · Cited by 32
“A germline mutation in the p16INK4A-binding domain of CDK4 has been described in at least six melanoma-prone families (Molven et al., 2005; Zuo et al., 1996).”
BackgroundA GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus
Mobuchon, L., Battistella, A., Bardel, C., Scélo, G., Renoud, A., Houy, A., Cassoux, N., Milder, M., Cancel‐Tassin, G., Cussenot, O., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0008-5 · Cited by 30
Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4
Chen, S., Guan, X., Wang, L., Li, B., Sang, X., Liu, Y. Z., & Zhao, Y. (2017) · Gene · doi:10.1016/j.gene.2017.09.009 · Cited by 28
CDKN2A and MC1R Mutations in Patients with Sporadic Multiple Primary Melanoma
Peris, K., Fargnoli, M. C., Pacifico, A., Surrenti, T., Stolz, W., Wolf, P., Soyer, H. P., & Chimenti, S. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22532.x · Cited by 27
“Mao et al , 1995 ) (GenBank accession number: L41934), and CDK4”
Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families
Yakobson, E., Shemesh, P., Azizi, E., Winkler, E., Lassam, N. J., Hogg, D., Brookes, S., Peters, G. G., Lotem, M., Zlotogorski, A., et al. (2000) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200505 · Cited by 28
Briollais, L., Chompret, A., Guilloud-Bataille, M., Paillerets, B. B.-D., Avril, M.-F., & Demenais, F. (2000) · International Journal of Epidemiology · doi:10.1093/ije/29.3.408 · Cited by 27
Lentigos, Melanocytic Naevi and Melanoma
Newton‐Bishop, J. (2010) · Wiley eBooks · doi:10.1002/9781444317633.ch54 · Cited by 39
Regulation of Cell Cycle Entry and Exit: A Single Cell Perspective
Coller, H. A. (2019) · Comprehensive physiology · doi:10.1002/cphy.c190014 · Cited by 34
“…from the cytokine TGF-β (409) and during senescence (7). p16INK4A, a member of the INK family of CDK inhibitors, is a tumor suppressor that is homozygously deleted or silenced via methylation at high frequency in melanoma and multiple different tumors (30, 233, 234, 259, 286, 359, 413, 521).”
Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells
Li, J., Xu, M., Yang, Z., Li, A., & Dong, J. (2010) · Cancer Investigation · doi:10.1080/07357900903286966 · Cited by 26
“A germ-line Arg24Cys (R24C) mutation in CDK4 was identified in familial melanoma patients (12, 13).”
BackgroundJeyakumar, A., Chua, T. C., Lam, A. K.-Y., & Gopalan, V. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102989 · Cited by 28
Helgadóttir, H., Höiom, V., Tuominen, R., Jönsson, G. B., Månsson‐Brahme, E., Olsson, H. L., & Hansson, J. (2015) · International Journal of Cancer · doi:10.1002/ijc.29595 · Cited by 31
Slomiany, P., Baker, T., Elliott, E., & Grossel, M. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20966 · Cited by 29
“For instance, cdk4 and cdk6 have distinct functions in tumorigenesis, in halting cellular proliferation, and in T-cell activation [Lucas et al., 1995a,b, 2004; Wolfel et al., 1995; Zuo et al., 1996; Costello et al., 1997; Timmermann et al., 1997; Easton et al., 1998; Nagasawa et al., 2001; Piboonniyom et al., 2002].”
BackgroundHino, S., Yamaoka, T., Yamashita, Y., Yamada, T., Hata, J., & Itakura, M. (2004) · Diabetologia · doi:10.1007/s00125-004-1522-4 · Cited by 29
“It is possible that CDK4 is regulated differently to CDK4 R24C since the amplification and overexpression of CDK4 has been observed in a wide spectrum of human tumours [34], whereas CDK4 R24C has been shown to be overexpressed only in sporadic and familial melanomas [9, 10].”
BackgroundA novel type of deletion in the CDKN2A gene identified in a melanoma‐prone family
Knappskog, S., Geisler, J., Arnesen, T., Lillehaug, J. R., & Lønning, P. E. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20379 · Cited by 27
“Except from a very few families reported to have germline mutations in the gene encoding cyclin dependent kinase 4 (Zuo et al., 1996; Soufir et al., 1998; Molven et al., 2005), CDKN2A is the only gene in which germline mutations have been linked to hereditary cases of malignant melanoma.”
Background
Metadata
- Authors
- Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- Venue
- Nature Genetics
- Published
- 1996-01
- Volume
- 12
- Issue
- 1
- Pages
- 97-99
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2051506850
- Cited by
- 818
- References
- 29
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 19 · 2019: 23 · 2018: 24 · 2017: 36 · 2016: 24 · 2015: 27 · 2014: 32 · 2013: 30 · 2012: 19
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- CDK4, germline mutations, familial melanoma, cyclin-dependent kinases, cyclin D, retinoblastoma protein phosphorylation, G1 cell cycle checkpoint, hereditary melanoma, tumor-specific antigens
- MeSH terms
- Base Sequence, Carrier Proteins, Female, Humans, Male, Melanoma, Molecular Sequence Data, Pedigree, Proto-Oncogene Proteins, DNA Primers, Polymorphism, Single-Stranded Conformational, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.